Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch

Neuro-Oncology

Volumn 14, Issue 10, 2012, Pages 1215-1226

  Floyd, Desiree H ^a   Kefas, Benjamin ^a   Seleverstov, Oleksandr ^a   Mykhaylyk, Olga ^b   Dominguez, Charli ^b   Comeau, Laurey ^a   Plank, Christian ^a   Purow, Benjamin ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

alpha secretase; cancer stem cells; GBM; Notch; YKL 40

Indexed keywords

ALPHA SECRETASE; ALPHA SECRETASE INHIBITOR; ENZYME INHIBITOR; INCB 3619; LIPOSOME; METHYL 7 [(HYDROXYAMINO)CARBONYL] 6 [(4 PHENYL 3,6 DIHYDROPYRIDIN 1(2H) YL)CARBONYL] 5 AZASPIRO[2.5]OCTANE 5 CARBOXYLATE; NANOPARTICLE; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; TREATMENT OUTCOME;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; LUCIFERASES; MAGNETICS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPIRO COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866948347     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos157     Document Type: Article

References (51)

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the US 2004-2006. 2010.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10): 987-996.
3. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18): 5821-5828.
4. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9): 3398-3403.
5. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66(15): 7445-7452.
6. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6): 2353-2363.
7. Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. Semin Cancer Biol. 2004;14(5): 320-328.
8. Bozkulak EC, Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol. 2009;29(21): 5679-5695.
9. Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5(2): 207-216.
10. LaVoie MJ, Selkoe DJ. The Notch ligands, jagged and delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 2003;278(36): 34427-34437.
11. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398(6727): 518-522.
12. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature. 1995;377(6547): 355-358.
13. Kefas B, Comeau L, Floyd DH, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 2009;29(48): 15161-15168.
14. Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010;9(6): 1618-1628.
15. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 2005;65(24): 11419-11428.
16. Niehrs C, Boutros M. Trafficking, acidification, and growth factor signaling. Sci Signal. 2010;3(134): pe26.
17. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291): 1052-1057.
18. Tian L, Wu X, Chi C, Han M, Xu T, Zhuang Y. ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int Immunol. 2008;20(9): 1181-1187.
19. Witters L, Scherle P, Friedman S, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008; 68(17): 7083-7089.
20. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10(1): 39-50.
21. Baumgart A, Seidl S, Vlachou P, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010;70(13): 5368-5378.
22. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glio-blastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5): 391-403.
23. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68(10): 3566-3572.
24. Kefas BA, Heimberg H, Vaulont S, et al. AICA-riboside induces apopto-sis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia. 2003;46(2): 250-254.
25. Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, Moller W, Plank C. Magnetic nanoparticle formulations for DNA and siRNA delivery. Journal of Magnetism and Magnetic Materials. 2007;311(1): 275-281.
26. Kowalski JB, Tallentire A. Substantiation of 25 kGy as a sterilization dose: a rational approach to establishing verification dose. Radiation Physics and Chemistry. 1999;54(1): 55-64.
27. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc. 2007;2(10): 2391-2411.
28. Snyder F, Stephens N. A simplified spectrophotometric determination of ester groups in lipids. Biochim Biophys Acta. 1959;34: 244-245.
29. Suzuki M, Mikami T, Matsumoto T, Suzuki S. Preparation and antitumor activity of O-palmitoyldextran phosphates, O-palmitoyldextrans, and dextran phosphate. Carbohydrate Research. 1977;53(2): 223-229.
30. Ferrari-Toninelli G, Bonini SA, Uberti D, et al. Targeting Notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro Oncol. 2010;12(12): 1231-1243.
31. Noseda M, Fu Y, Niessen K, et al. Smooth Muscle alpha-actin is a direct target of Notch/CSL. Circ Res. 2006;98(12): 1468-1470.
32. Nam Y, Sliz P, Pear WS, Aster JC, Blacklow SC. Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. Proc Natl Acad Sci USA. 2007;104(7): 2103-2108.
33. Dumortier A, Jeannet R, Kirstetter P, et al. Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol. 2006;26(1): 209-220.
34. Lim JW, Kim H, Kim KH. The Ku antigen-recombination signal-binding protein Jkappa complex binds to the nuclear factor-kappaB p50 promoter and acts as a positive regulator of p50 expression in human gastric cancer cells. J Biol Chem. 2004;279(1): 231-237.
35. He G, Siddik ZH, Huang Z, et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 2005;24(18): 2929-2943.
36. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1): 98-110.
37. Bhat KP, Pelloski CE, Zhang Y, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and-2. FEBS Lett. 2008;582(21-22): 3193-3200.
38. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12(19): 5698-5704.
39. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27(4): 572-578.
40. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005;96(3): 183-190.
41. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblas-toma. Clin Cancer Res. 2005;11(9): 3326-3334.
42. Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol. 2009;511: 159-184.
43. Lilja A, Nordborg C, Brun A, Salford LG, Aman P. Expression of the IL-6 family cytokines in human brain tumors. Int J Oncol. 2001;19(3): 495-499.
44. Penuelas S, Anido J, Prieto-Sanchez RM, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4): 315-327.
45. Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glio-blastoma. Genes Dev. 2010;24(16): 1731-1745.
46. Mohamet L, Heath JK, Kimber SJ. Determining the LIF-sensitive period for implantation using a LIF-receptor antagonist. Reproduction. 2009;138(5): 827-836.
47. Mayer M, Bhakoo K, Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development. 1994;120(1): 143-153.
48. Bonni A, Sun Y, Nadal-Vicens M, et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science. 1997;278(5337): 477-483.
49. Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. Neuron. 2000;26(2): 395-404.
50. Livneh Z. Keeping mammalian mutation load in check: regulation of the activity of error-prone DNA polymerases by p53 and p21. Cell Cycle. 2006;5(17): 1918-1922.
51. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3): 469-479.